Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 6

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 6
---
, 2025, on a retroactive basis 

See accompanying notes to the condensed consolidated financial statements.

 7Table of Contents

BIONEXUS GENE LAB CORP. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY AS OF SEPTEMBER 30, 2025 AND 2024 (Amount expressed in United States Dollars (“US$)) (Unaudited)

  Common stock  Additional     Accumulated other   Total    Number of shares  Amount   paid in capital  Accumulated deficit  comprehensive losses  stockholders’equity Balance as of December 31, 2024 *  1,796,766  $17,332,315  $(5,011,891) $(3,442,620) $(555,000) $8,322,804 Net loss for the period  -   -   -   (623,327)  -   (623,327)Foreign currency translation gain  -   -   -   -   72,159   72,159 Balance as of March 31, 2025 *  1,796,766  $17,332,315  $(5,011,891) $(4,065,947) $(482,841) $7,771,636 Net loss for the period  -   -   -   (616,172)  -   (616,172)Round down shares #   (169)  (505)              (505)Foreign currency translation gain  -   -   -   -   367,078   367,078 Balance as of June 30, 2025 *  1,796,597  $17,331,810  $(5,011,891) $(4,682,119) $(115,763) $7,522,037 Net loss for the period  -   -   -   (708,991)  -   (708,991)Foreign currency translation gain  -   -   -   -   3,216   3,216 Balance as of